USA Health Homepage

Navigation

19-362 - Safety and Pharmacokinetics Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

Status: open

A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

Treatment for Advanced Solid Tumors

Contact Us Or call (251) 445-9834

Description


The purpose of this study is to assess the safety and pharmacokinetics of MK-5890 when administered alone and in combination with pembrolizumab (MK-3475) in adults with advanced solid tumors. The initial course of  MK-5890 monotherapy or MK-5890 plus pembrolizumab combination therapy  will be for up to 35 administrations (approximately 2 years). The safety and pharmacokinetics of MK-5890 when administered with pembrolizumab, pemetrexed and carboplatin will also be assessed in adults with non-squamous non-small cell lung cancer (NSCLC).

Sponsors

This trial is sponsored by University of Chicago.
Learn More at ClinicalTrials.gov

Location

Mitchell Cancer Institute
1660 SpringHill Avenue
Mobile, AL 36604
(251) 665-8000

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.